LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 449

Search options

  1. Article ; Online: Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer.

    Kaira, Kyoichi

    Internal medicine (Tokyo, Japan)

    2022  Volume 62, Issue 12, Page(s) 1705–1706

    MeSH term(s) Humans ; Diagnosis, Differential ; Hematologic Neoplasms/diagnosis ; Lung Neoplasms/diagnosis ; Lung Neoplasms/pathology ; Bone Neoplasms/diagnostic imaging ; Bone Neoplasms/secondary ; Bone Marrow Diseases
    Language English
    Publishing date 2022-11-09
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.1050-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.

    Kaira, Kyoichi / Imai, Hisao / Kagamu, Hiroshi

    Lung cancer (Amsterdam, Netherlands)

    2024  Volume 189, Page(s) 107501

    MeSH term(s) Humans ; Sunitinib/therapeutic use ; Thymoma/drug therapy ; Lung Neoplasms ; Thymus Neoplasms/drug therapy ; Phenylurea Compounds ; Quinolines
    Chemical Substances lenvatinib (EE083865G2) ; Sunitinib (V99T50803M) ; Phenylurea Compounds ; Quinolines
    Language English
    Publishing date 2024-02-09
    Publishing country Ireland
    Document type Letter
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2024.107501
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Reply to: Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.

    Kaira, Kyoichi

    Cancer chemotherapy and pharmacology

    2018  Volume 82, Issue 2, Page(s) 369

    MeSH term(s) Carcinoma, Pancreatic Ductal ; Humans ; Pancreatic Neoplasms
    Language English
    Publishing date 2018-06-25
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-018-3628-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Small cell lung carcinoma initially presenting as giant left ventricular mass.

    Yamaguchi, Ou / Kaira, Kyoichi / Imai, Hisao / Kagamu, Hiroshi

    Japanese journal of clinical oncology

    2023  Volume 54, Issue 3, Page(s) 359–360

    MeSH term(s) Humans ; Small Cell Lung Carcinoma/diagnostic imaging ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/surgery ; Lung Neoplasms/pathology ; Biomarkers, Tumor
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2023-12-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 190978-2
    ISSN 1465-3621 ; 0368-2811
    ISSN (online) 1465-3621
    ISSN 0368-2811
    DOI 10.1093/jjco/hyad173
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.

    Ito, Koki / Yamaguchi, Ou / Kaira, Kyoichi / Imai, Hisao / Kagamu, Hiroshi

    Lung cancer (Amsterdam, Netherlands)

    2023  Volume 179, Page(s) 107193

    MeSH term(s) Humans ; Thymoma ; Lung Neoplasms ; Phenylurea Compounds ; Quinolines ; Thymus Neoplasms/pathology ; Liver Neoplasms
    Chemical Substances lenvatinib (EE083865G2) ; Phenylurea Compounds ; Quinolines
    Language English
    Publishing date 2023-04-10
    Publishing country Ireland
    Document type Letter
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2023.107193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Advanced Research on Immune Checkpoint Inhibitor Therapy.

    Imai, Hisao / Kaira, Kyoichi / Kagamu, Hiroshi

    Journal of clinical medicine

    2022  Volume 11, Issue 18

    Abstract: The human body has an inherent immune surveillance mechanism that eliminates cancer cells and suppresses the development of cancer [ ... ]. ...

    Abstract The human body has an inherent immune surveillance mechanism that eliminates cancer cells and suppresses the development of cancer [...].
    Language English
    Publishing date 2022-09-14
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11185392
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L).

    Ozawa, Yuichi / Koh, Yasuhiro / Hase, Tetsunari / Chibana, Kenji / Kaira, Kyoichi / Okishio, Kyoichi / Ichihara, Eiki / Murakami, Shuji / Shimokawa, Mototsugu / Yamamoto, Nobuyuki

    Therapeutic advances in medical oncology

    2024  Volume 16, Page(s) 17588359231225046

    Abstract: Background: ALK-tyrosine kinase inhibitors (ALK-TKIs) are effective for treating non-small-cell lung cancer with : Objectives: This study will evaluate the efficacy and safety of brigatinib in the real world and explore factors related to its ... ...

    Abstract Background: ALK-tyrosine kinase inhibitors (ALK-TKIs) are effective for treating non-small-cell lung cancer with
    Objectives: This study will evaluate the efficacy and safety of brigatinib in the real world and explore factors related to its efficacy, safety, and resistance mechanisms.
    Design: Prospective observational study.
    Ethics: This study is approved by the Ethics Committee of Wakayama Medical University. Written informed consent will be obtained from all patients before study-related procedures.
    Methods and analysis: This study comprises three cohorts. Cohorts A, B, and 0 will enroll patients receiving alectinib as the first ALK-TKI, receiving alectinib as the first ALK-TKI and subsequently cytotoxic agents and/or lorlatinib after alectinib, and without a history of ALK-TKI, respectively. Overall, 100, 30, and 50 patients will be enrolled in Cohorts A, B, and 0, respectively. Circulating tumor DNA before starting brigatinib and at disease progression will be analyzed in all cohorts using a hypersensitive next-generation sequencing (NGS) PGDx Elio plasma resolve panel. Serum protein levels will be analyzed using the Milliplex xMAP assay system with a Luminex 200 (Luminex, Austin, USA). The enrollment period is 31 months and the patients will be observed for 2 years after enrollment. Archived tissues will be collected for NGS analysis, gene expression analysis, and immunohistochemistry staining 1 year after completion of registration. Quality of life and safety evaluation using electronic patient-reported outcomes will be investigated.
    Discussion: This study will elucidate predictors of ALK-TKI efficacy and resistance mechanisms and evaluate the efficacy and safety of brigatinib in a real-world setting. The results will provide crucial information for establishing treatment strategies, discovering novel biomarkers, and developing new therapeutic agents.
    Trial registration: UMIN000042439.
    Language English
    Publishing date 2024-01-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359231225046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer.

    Kaira, Kyoichi / Ikezawa, Tomohiro / Inoue, Tsutomu / Imai, Hisao / Okada, Hirokazu / Kagamu, Hiroshi

    Journal of chemotherapy (Florence, Italy)

    2023  Volume 36, Issue 1, Page(s) 82–83

    MeSH term(s) Humans ; Antibodies, Antineutrophil Cytoplasmic ; Immune Checkpoint Inhibitors ; Lung Neoplasms ; Glomerulonephritis
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic ; Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-05-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 1036294-0
    ISSN 1973-9478 ; 1120-009X
    ISSN (online) 1973-9478
    ISSN 1120-009X
    DOI 10.1080/1120009X.2023.2212207
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.

    Oriuchi, Noboru / Endoh, Hideki / Kaira, Kyoichi

    International journal of molecular sciences

    2022  Volume 23, Issue 16

    Abstract: Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG- ... ...

    Abstract Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactive cells such as activated T-cells and macrophages, which show increased glucose metabolism and apparent progression on morphological imaging. Cellular metabolism and function are critical determinants of the viability of active cells in the tumor microenvironment, which would be novel targets of therapies, such as tumor immunity, metabolism, and genetic mutation. Considering tumor heterogeneity and variation in therapy response specific to the mechanisms of therapy, appropriate response evaluation is required. Radiomics approaches, which combine objective image features with a machine learning algorithm as well as pathologic and genetic data, have remarkably progressed over the past decade, and PET radiomics has increased quality and reliability based on the prosperous publications and standardization initiatives. PET and multimodal imaging will play a definitive role in personalized therapeutic strategies by the precise monitoring in future cancer therapy.
    MeSH term(s) Fluorodeoxyglucose F18 ; Humans ; Multimodal Imaging ; Neoplasms/diagnostic imaging ; Neoplasms/genetics ; Neoplasms/therapy ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography ; Reproducibility of Results ; Tumor Microenvironment
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2022-08-20
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23169394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer.

    Shinomiya, Shun / Kaira, Kyoichi / Mouri, Atsuto / Kagamu, Hiroshi

    Japanese journal of clinical oncology

    2021  Volume 51, Issue 7, Page(s) 1179–1180

    MeSH term(s) Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Immunotherapy ; Lung Neoplasms/drug therapy ; Programmed Cell Death 1 Receptor ; Sarcoidosis/drug therapy ; Skin Diseases
    Chemical Substances Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2021-03-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 190978-2
    ISSN 1465-3621 ; 0368-2811
    ISSN (online) 1465-3621
    ISSN 0368-2811
    DOI 10.1093/jjco/hyab043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top